Nice work, on scouting the e-commerce sites.
I do not have the time to look over these sites as you and others do.
From a fundamentalist stock analysis viewpoint, one currently lacks the info (perhaps until next 1 or 2 earnings calls), as to where DRIO is at in product development and marketing.
Technical analysis is also vapourous as to what we are seeing in stock price (is it basingat a now higher price range, or at its new resistance price level)?
I am beginning to suspect (as you and others), that DRIO has thrown a hay-el mary
product introduction pass, type of thing. 'Get it out there and lets see how it goes'?
To me, DRIO is being very evasive as to current status of the DRIO mobile reader.
The user comment you high-lighted seems to tell us there are operational problems with the initial design of the device (and maybe even in its manufacturing quality)?
There also is seemingly a lack of acceptance of the product; commercially, user-wise, and professional care provider awareness of?
This leads me to surmise, DRIO is constrained in knowing how to get consumers to want to use the device. If professional care providers are concerned as to the pricing efficiency of the DRIO device test strips (on their medical care clients
budgets), that implies an uphill battle for acceptance? Reality maybe a lot different than the dream, so to speak.
If one goes to the druggist, they will find displayed up to 3 or 4 different brand name devices currently being sold, that are comfortably already established and trusted. I should think large scale medical device manufacturers would be keen, to attempt their own versions of what DRIO is doing. <---And DRIO, has no $$s legs to stand on, to defend itself therein.
Unless starling sales contracts are achieved at the upcoming Feb Paris Diabetes Show, I do not expect more than .02-.10 stock price pop effect thereof. We might also hope for some kind of partnering interest to surface at that coming conference?
That might get us .20-.45 stock price rise.
DRIO still is off-the-radar of consumers and care providers?
The potential of the diabetic mobile communicating online reader may be at an earlier stage of acceptance, then many of us had thought.
DRIO has never made clear what segment of the diabetic income user spectrum, it has targeted. The 1-3% of diabetic device market DRIO has hoped for (to make it profitable company), might just be the high $s income segment? So only certain doctors would be servicing that patient segment.
And, are we just selling predominantly through online ordering?
Also, are we using online buyers as a means of developing a low-ball form of pre-clinical trial datum, to support our FDA Approval?
